A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes (Q90388293)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

title

A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

author name string

Lauren Kolb

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

Melissa Skibba

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

Markus Hartmann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

René Blöcher

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

Ewgenij Proschak

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

John D Imig

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

publication date

21 July 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

page(s)

2235-2246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril

13 April 2020

cites work

1 reference

12 December 2020

Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial

1 reference

12 December 2020

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study

1 reference

12 December 2020

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

12 December 2020

Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature

1 reference

12 December 2020

Long-term caffeine consumption exacerbates renal failure in obese, diabetic, ZSF1 (fa-fa(cp)) rats

1 reference

12 December 2020

Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

1 reference

12 December 2020

Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist

1 reference

12 December 2020

Ramipril-Associated Hepatotoxicity

1 reference

12 December 2020

Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control

1 reference

12 December 2020

The metabolic syndrome

1 reference

12 December 2020

Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.

1 reference

12 December 2020

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

1 reference

12 December 2020

Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice.

1 reference

12 December 2020

Dyslipidemia and the progression of renal disease in chronic renal failure patients

1 reference

12 December 2020

Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy

1 reference

12 December 2020

Rosiglitazone ameliorates cisplatin-induced renal injury in mice

1 reference

12 December 2020

Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect

1 reference

12 December 2020

Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes

1 reference

12 December 2020

Inflammation and metabolic disorders

1 reference

12 December 2020

Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production

1 reference

12 December 2020

Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism

1 reference

12 December 2020

The pathogenesis of diabetic nephropathy

1 reference

12 December 2020

Effects of weight loss on nonalcoholic fatty liver disease

1 reference

12 December 2020

PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta

1 reference

12 December 2020

Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia

1 reference

12 December 2020

The metabolic syndrome: definition, global impact, and pathophysiology

1 reference

12 December 2020

Pioglitazone: side effect and safety profile

1 reference

12 December 2020

Targeting epoxides for organ damage in hypertension

1 reference

12 December 2020

Oxidative stress in early diabetic nephropathy: fueling the fire

1 reference

12 December 2020

Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction

1 reference

12 December 2020

Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance

1 reference

12 December 2020

Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats

1 reference

12 December 2020

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States

1 reference

12 December 2020

Effects of cytochrome P-450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC)

1 reference

12 December 2020

Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats

1 reference

12 December 2020

Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy

1 reference

12 December 2020

Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling

1 reference

12 December 2020

Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes

1 reference

12 December 2020

Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice

1 reference

12 December 2020

Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated phosphorylation

1 reference

12 December 2020

Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats

1 reference

12 December 2020

The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010.

1 reference

12 December 2020

Ramipril-induced liver injury: case report and review of the literature.

1 reference

12 December 2020

Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition.

1 reference

12 December 2020

Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat

1 reference

12 December 2020

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

1 reference

12 December 2020

Diabetic kidney disease: a report from an ADA Consensus Conference

1 reference

12 December 2020

Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.

1 reference

12 December 2020

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

1 reference

12 December 2020

Effect of n-3 PUFA supplementation at different EPA:DHA ratios on the spontaneously hypertensive obese rat model of the metabolic syndrome

1 reference

12 December 2020

Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice

1 reference

12 December 2020

Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice

1 reference

12 December 2020

Perirenal Fat Promotes Renal Arterial Endothelial Dysfunction in Obese Swine through Tumor Necrosis Factor-α.

1 reference

12 December 2020

PPARγ Regulation in Hypertension and Metabolic Syndrome.

1 reference

12 December 2020

N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators

1 reference

12 December 2020

Soluble epoxide hydrolase: A potential target for metabolic diseases

1 reference

12 December 2020

Complication in diabetic nephropathy

1 reference

12 December 2020

Emerging therapeutics for the treatment of diabetic nephropathy

1 reference

12 December 2020

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

1 reference

12 December 2020

NAFLD and diabetes mellitus

1 reference

12 December 2020

Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus

1 reference

12 December 2020

10.1007/S00125-018-4685-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30032428 AND SRC:MED&resulttype=core&format=json

13 April 2020

PubMed publication ID

30032428

1 reference